Surrozen Q2 net loss $9.4M; cash runway extended into 2025 on prioritization

Surrozen, Inc./DE

2023-Q2 EPS reported -$0.79

Net loss of $9.4M improved from $13.9M YoY; cash and securities $53.4M (down from $61.7M in Q1).
R&D expenses fell to $6.9M from $9.6M YoY; G&A expenses to $3.3M from $4.5M YoY.
SZN-043 Phase 1a enrollment continues; safety data expected by end of 2023; Phase 1b in alcoholic hepatitis planned for 2024.
SZN-1326 Phase 1a enrollment continues; Phase 1b in ulcerative colitis planned for 2024, proof-of-concept data expected H2 2024.
Boehringer Ingelheim partnership may trigger $10M milestone in 2024 upon Fzd-4 candidate nomination.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Surrozen, Inc./DE reported second quarter ended June 30, 2023 results: net income Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i.

Period: second quarter ended June 30, 2023
Net income: Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period i
Result: reported results

Exact text from the filing

Net loss for the second quarter ended June 30, 2023 was $9.4 million, as compared to $13.9 million for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Surrozen, Inc./DE filing history →

Source: SEC EDGAR

accession 0000950170-23-040611

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.